WIKIMEDIA, ERNESTO DEL ADUILA III, NHGRIBiotech investors will soon have one more CRISPR/Cas9-based company to back, after CRISPR Therapeutics filed for an initial public offering (IPO) on Friday (September 9). The firm, which was cofounded by CRISPR/Cas9 pioneer Emanuelle Charpentier as Inception Genomics in 2013, is looking to raise $90 million from the IPO and will join the ranks of Intellia Therapeutics and Editas Medicine, which both went public earlier this year. Like the other publicly traded, gene-editing companies, CRISPR Therapeutics will sell its shares on the Nasdaq exchange.
According to the IPO registration document that CRISPR Therapeutics filed with the US Securities and Exchange Commission, the firm brokered a pretty sweet deal before the IPO even gets underway. Bayer—the company that CRISPR Therapeutics has been collaborating with on Casebia, a joint effort to develop gene therapies—has agreed to kick in $35 million in a separate deal at the IPO price.
